The company completed the enrollment for its Phase 2 trial of VK2735, a dual agonist targeting obesity, and entered a significant manufacturing agreement with CordenPharma, focusing on securing ...

One of the reasons injectable GLP-1 peptides are difficult to manufacture and scale is the need for a sterile production environment, Mimoun Ayoub, global head, peptides and oligonucleotides platforms ...

Viking Therapeutics jumped by 11.43 percent on Wednesday to end at $29.55 each as investor sentiment was fueled by news that it partnered with CordenPharma for the production of its weight loss ...

San Diego–based Viking VKTX said Tuesday it has signed a broad manufacturing agreement with CordenPharma, a privately held Swiss company, to support the commercialization of its oral obesity ...

Viking Therapeutics VKTX signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and manufacturing organization (CDMO), for both the oral and subcutaneous (SC ...

Viking Therapeutics (NASDAQ:VKTX) has announced a significant multi-year manufacturing agreement with CordenPharma, a leading contract development and manufacturing organization (CDMO), to ensure long ...

CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735. CordenPharma provides large-scale ...

Yesterday, Viking signed a "broad manufacturing agreement" with Germany's CordenPharma to produce for it a "multi-ton annual supply" of Viking's own VK2735 GLP-1 weight-loss drug. VK2735 is still ...

BASEL, Switzerland, March 5, 2025 /PRNewswire/ -- Following its 16 July 2024 announcement, CordenPharma is pleased to share significant progress on its growth initiatives with a >€1 billion strategic ...